Technical Analysis for NGM - NGM Biopharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 13.9 1.24% 0.17
NGM closed up 1.24 percent on Monday, June 17, 2019, on 1.5 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Up
See historical NGM trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Inside Day Range Contraction 0.00%
20 DMA Resistance Bearish 1.24%
Fell Below 20 DMA Bearish 1.61%
Crossed Above 20 DMA Bullish -0.71%
Outside Day Range Expansion -0.71%
20 DMA Resistance Bearish 1.09%
MACD Bullish Signal Line Cross Bullish 1.09%
Narrow Range Bar Range Contraction 1.09%

Older signals for NGM ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include NGM282, an engineered variant of the FGF19 human hormone in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that selectively activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b early proof-of-concept clinical trials for use in the treatment of type 2 diabetes and NASH; and NGM386 and NGM395, which are engineered variants of the GDF15 human hormone for use in the treatment of obesity. Its products under development also comprise NGM120, an antagonistic antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase 1 clinical trials to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome; NGM217, an antibody in Phase 1 clinical trials to restore pancreatic islet function and increase insulin production in patients with diabetes; and NGM621, an antibody in preclinical studies to decrease levels of a protein implicated in the dry form of age-related macular degeneration. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp., MedImmune Limited, and JDRF International. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Diabetes Pharmacy Monoclonal Antibodies Obesity Age Related Macular Degeneration Treatment Of Obesity
Is NGM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 18.75
52 Week Low 12.0
Average Volume 92,196
200-Day Moving Average 0.0
50-Day Moving Average 14.7174
20-Day Moving Average 14.0365
10-Day Moving Average 13.659
Average True Range 0.8584
ADX 21.64
+DI 12.6302
-DI 16.6045
Chandelier Exit (Long, 3 ATRs ) 12.7448
Chandelier Exit (Short, 3 ATRs ) 14.5752
Upper Bollinger Band 15.2013
Lower Bollinger Band 12.8717
Percent B (%b) 0.44
BandWidth 16.59673
MACD Line -0.259
MACD Signal Line -0.3112
MACD Histogram 0.0522
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.61
Resistance 3 (R3) 14.60 14.36 14.49
Resistance 2 (R2) 14.36 14.18 14.36 14.45
Resistance 1 (R1) 14.13 14.07 14.25 14.14 14.41
Pivot Point 13.89 13.89 13.95 13.89 13.89
Support 1 (S1) 13.66 13.71 13.78 13.67 13.39
Support 2 (S2) 13.42 13.60 13.42 13.35
Support 3 (S3) 13.19 13.42 13.31
Support 4 (S4) 13.20